Τίτλος:
Prevalence, clinical characteristics and outcomes of Guillain−Barré syndrome spectrum associated with COVID-19: A systematic review and meta-analysis
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
Background and purpose: Mounting evidence supports an association between Guillain−Barré syndrome spectrum (GBSs) and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. However, GBSs in the setting of coronavirus disease 2019 (COVID-19) remains poorly characterized, whilst GBSs prevalence amongst COVID-19 patients has not been previously systematically evaluated using a meta-analytical approach. Methods: A systematic review and meta-analysis of observational cohort and case series studies reporting on the occurrence, clinical characteristics and outcomes of patients with COVID-19-associated GBSs was performed. A random-effects model was used to calculate pooled estimates and odds ratios (ORs) with corresponding 95% confidence intervals (CIs), compared to non-COVID-19, contemporary or historical GBSs patients. Results: Eighteen eligible studies (11 cohorts, seven case series) were identified including a total of 136,746 COVID-19 patients. Amongst COVID-19 patients, including hospitalized and non-hospitalized cases, the pooled GBSs prevalence was 0.15‰ (95% CI 0%–0.49‰; I2 = 96%). Compared with non-infected contemporary or historical controls, patients with SARS-CoV-2 infection had increased odds for demyelinating GBSs subtypes (OR 3.27, 95% CI 1.32%–8.09%; I2 = 0%). In SARS-CoV-2-infected patients, olfactory or concomitant cranial nerve involvement was noted in 41.4% (95% CI 3.5%–60.4%; I2 = 46%) and 42.8% (95% CI 32.8%–53%; I2 = 0%) of the patients, respectively. Clinical outcomes including in-hospital mortality were comparable between COVID-19 GBSs patients and non-infected contemporary or historical GBSs controls. Conclusion: GBSs prevalence was estimated at 15 cases per 100,000 SARS-CoV-2 infections. COVID-19 appears to be associated with an increased likelihood of GBSs and with demyelinating GBSs variants in particular. © 2021 European Academy of Neurology
Συγγραφείς:
Palaiodimou, L.
Stefanou, M.-I.
Katsanos, A.H.
Fragkou, P.C.
Papadopoulou, M.
Moschovos, C.
Michopoulos, I.
Kokotis, P.
Bakirtzis, C.
Naska, A.
Vassilakopoulos, T.I.
Chroni, E.
Tsiodras, S.
Tsivgoulis, G.
Περιοδικό:
European Journal of Paediatric Neurology
Εκδότης:
John Wiley and Sons Inc
Λέξεις-κλειδιά:
immunoglobulin, adult; clinical feature; clinical outcome; controlled study; coronavirus disease 2019; cranial neuropathy; disease association; Guillain Barre syndrome; hospital patient; human; in-hospital mortality; middle aged; olfactory nerve disease; plasmapheresis; prevalence; Review; systematic review; Guillain Barre syndrome; hospital mortality; meta analysis; prevalence, COVID-19; Guillain-Barre Syndrome; Hospital Mortality; Humans; Prevalence; SARS-CoV-2
